Empiric long-term amiodarone prophylaxis following myocardial infarction: A meta-analysis

Dawn G. Zarembski, Paul E. Nolan, Marion K Slack, Anthony C. Caruso

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: The prophylactic administration of amiodarone following acute myocardial infarction has been investigated in several small trials. This study combined the results of these small trials in a metaanalysis to determine the effects of prophylactic low-dose amiodarone on mortality following acute myocardial infarction. Methods: Four prospective, randomized, placebo-controlled trials, which investigated the prophylactic administration of low-dose amiodarone (200 to 400 mg/d) to patients after acute myocardial infarction, were selected from the current literature according to strict inclusion criteria. A total of 1140 patients, 566 in the amiodarone-treated group and 574 in the placebo-treated group, were included in the analysis. Sudden cardiac death, cardiac mortality, and total mortality were the end points of interest. In addition, the effect of impaired left ventricular function (ejection fraction, <45%) on total mortality was assessed. Data were aggregated by using the Mantel-Haenszel method to obtain final summary statistics for these end points. Results: Patients treated with low-dose amiodarone exhibited a lower incidence of sudden cardiac death (3.1%) and total mortality (6.1%) when compared with patients treated with placebo (6.9% and 11.2%, respectively; both P<.01; and 95% confidence interval [CI], 0.011 to 0.065 and 0.013 to 0.082, respectively). There was no significant difference between the amiodarone- and placebo-treated groups with respect to cardiac mortality (2.6% vs 3.7%, respectively; P=.26; and 95% CI, -0.012 to 0.032). For patients with a left ventricular ejection fraction of less than 45%, total mortality was 5.5% in the amiodarone-treated group and 9.4% in the placebo-treated group (P=.30; CI, -0.023 to 0.101). Conclusions: Although further data from ongoing large, randomized trials are needed, this meta-analysis suggests that the prophylactic administration of low-dose amiodarone to patients following acute myocardial infarction reduces the incidence of both sudden cardiac death and total mortality. The benefits of low-dose amiodarone may be limited to patients with preserved left ventricular function.

Original languageEnglish (US)
Pages (from-to)2661-2667
Number of pages7
JournalArchives of Internal Medicine
Volume153
Issue number23
StatePublished - Dec 13 1993

Fingerprint

Amiodarone
Meta-Analysis
Myocardial Infarction
Mortality
Placebos
Sudden Cardiac Death
Confidence Intervals
Left Ventricular Function
Stroke Volume
Incidence
Randomized Controlled Trials

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Empiric long-term amiodarone prophylaxis following myocardial infarction : A meta-analysis. / Zarembski, Dawn G.; Nolan, Paul E.; Slack, Marion K; Caruso, Anthony C.

In: Archives of Internal Medicine, Vol. 153, No. 23, 13.12.1993, p. 2661-2667.

Research output: Contribution to journalArticle

Zarembski, Dawn G. ; Nolan, Paul E. ; Slack, Marion K ; Caruso, Anthony C. / Empiric long-term amiodarone prophylaxis following myocardial infarction : A meta-analysis. In: Archives of Internal Medicine. 1993 ; Vol. 153, No. 23. pp. 2661-2667.
@article{4578324ee16d453c86ad32974eae3315,
title = "Empiric long-term amiodarone prophylaxis following myocardial infarction: A meta-analysis",
abstract = "Background: The prophylactic administration of amiodarone following acute myocardial infarction has been investigated in several small trials. This study combined the results of these small trials in a metaanalysis to determine the effects of prophylactic low-dose amiodarone on mortality following acute myocardial infarction. Methods: Four prospective, randomized, placebo-controlled trials, which investigated the prophylactic administration of low-dose amiodarone (200 to 400 mg/d) to patients after acute myocardial infarction, were selected from the current literature according to strict inclusion criteria. A total of 1140 patients, 566 in the amiodarone-treated group and 574 in the placebo-treated group, were included in the analysis. Sudden cardiac death, cardiac mortality, and total mortality were the end points of interest. In addition, the effect of impaired left ventricular function (ejection fraction, <45{\%}) on total mortality was assessed. Data were aggregated by using the Mantel-Haenszel method to obtain final summary statistics for these end points. Results: Patients treated with low-dose amiodarone exhibited a lower incidence of sudden cardiac death (3.1{\%}) and total mortality (6.1{\%}) when compared with patients treated with placebo (6.9{\%} and 11.2{\%}, respectively; both P<.01; and 95{\%} confidence interval [CI], 0.011 to 0.065 and 0.013 to 0.082, respectively). There was no significant difference between the amiodarone- and placebo-treated groups with respect to cardiac mortality (2.6{\%} vs 3.7{\%}, respectively; P=.26; and 95{\%} CI, -0.012 to 0.032). For patients with a left ventricular ejection fraction of less than 45{\%}, total mortality was 5.5{\%} in the amiodarone-treated group and 9.4{\%} in the placebo-treated group (P=.30; CI, -0.023 to 0.101). Conclusions: Although further data from ongoing large, randomized trials are needed, this meta-analysis suggests that the prophylactic administration of low-dose amiodarone to patients following acute myocardial infarction reduces the incidence of both sudden cardiac death and total mortality. The benefits of low-dose amiodarone may be limited to patients with preserved left ventricular function.",
author = "Zarembski, {Dawn G.} and Nolan, {Paul E.} and Slack, {Marion K} and Caruso, {Anthony C.}",
year = "1993",
month = "12",
day = "13",
language = "English (US)",
volume = "153",
pages = "2661--2667",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "23",

}

TY - JOUR

T1 - Empiric long-term amiodarone prophylaxis following myocardial infarction

T2 - A meta-analysis

AU - Zarembski, Dawn G.

AU - Nolan, Paul E.

AU - Slack, Marion K

AU - Caruso, Anthony C.

PY - 1993/12/13

Y1 - 1993/12/13

N2 - Background: The prophylactic administration of amiodarone following acute myocardial infarction has been investigated in several small trials. This study combined the results of these small trials in a metaanalysis to determine the effects of prophylactic low-dose amiodarone on mortality following acute myocardial infarction. Methods: Four prospective, randomized, placebo-controlled trials, which investigated the prophylactic administration of low-dose amiodarone (200 to 400 mg/d) to patients after acute myocardial infarction, were selected from the current literature according to strict inclusion criteria. A total of 1140 patients, 566 in the amiodarone-treated group and 574 in the placebo-treated group, were included in the analysis. Sudden cardiac death, cardiac mortality, and total mortality were the end points of interest. In addition, the effect of impaired left ventricular function (ejection fraction, <45%) on total mortality was assessed. Data were aggregated by using the Mantel-Haenszel method to obtain final summary statistics for these end points. Results: Patients treated with low-dose amiodarone exhibited a lower incidence of sudden cardiac death (3.1%) and total mortality (6.1%) when compared with patients treated with placebo (6.9% and 11.2%, respectively; both P<.01; and 95% confidence interval [CI], 0.011 to 0.065 and 0.013 to 0.082, respectively). There was no significant difference between the amiodarone- and placebo-treated groups with respect to cardiac mortality (2.6% vs 3.7%, respectively; P=.26; and 95% CI, -0.012 to 0.032). For patients with a left ventricular ejection fraction of less than 45%, total mortality was 5.5% in the amiodarone-treated group and 9.4% in the placebo-treated group (P=.30; CI, -0.023 to 0.101). Conclusions: Although further data from ongoing large, randomized trials are needed, this meta-analysis suggests that the prophylactic administration of low-dose amiodarone to patients following acute myocardial infarction reduces the incidence of both sudden cardiac death and total mortality. The benefits of low-dose amiodarone may be limited to patients with preserved left ventricular function.

AB - Background: The prophylactic administration of amiodarone following acute myocardial infarction has been investigated in several small trials. This study combined the results of these small trials in a metaanalysis to determine the effects of prophylactic low-dose amiodarone on mortality following acute myocardial infarction. Methods: Four prospective, randomized, placebo-controlled trials, which investigated the prophylactic administration of low-dose amiodarone (200 to 400 mg/d) to patients after acute myocardial infarction, were selected from the current literature according to strict inclusion criteria. A total of 1140 patients, 566 in the amiodarone-treated group and 574 in the placebo-treated group, were included in the analysis. Sudden cardiac death, cardiac mortality, and total mortality were the end points of interest. In addition, the effect of impaired left ventricular function (ejection fraction, <45%) on total mortality was assessed. Data were aggregated by using the Mantel-Haenszel method to obtain final summary statistics for these end points. Results: Patients treated with low-dose amiodarone exhibited a lower incidence of sudden cardiac death (3.1%) and total mortality (6.1%) when compared with patients treated with placebo (6.9% and 11.2%, respectively; both P<.01; and 95% confidence interval [CI], 0.011 to 0.065 and 0.013 to 0.082, respectively). There was no significant difference between the amiodarone- and placebo-treated groups with respect to cardiac mortality (2.6% vs 3.7%, respectively; P=.26; and 95% CI, -0.012 to 0.032). For patients with a left ventricular ejection fraction of less than 45%, total mortality was 5.5% in the amiodarone-treated group and 9.4% in the placebo-treated group (P=.30; CI, -0.023 to 0.101). Conclusions: Although further data from ongoing large, randomized trials are needed, this meta-analysis suggests that the prophylactic administration of low-dose amiodarone to patients following acute myocardial infarction reduces the incidence of both sudden cardiac death and total mortality. The benefits of low-dose amiodarone may be limited to patients with preserved left ventricular function.

UR - http://www.scopus.com/inward/record.url?scp=0027360009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027360009&partnerID=8YFLogxK

M3 - Article

C2 - 7504440

AN - SCOPUS:0027360009

VL - 153

SP - 2661

EP - 2667

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 23

ER -